Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
for Atrial Fibrillation (AF)
Drug: Abelacimab
150 locations incl. Birmingham
Sponsor: Anthos Therapeutics, Inc.
Sex: All·Age: 65+
Code: NCT05712200·Phase 3·Recruiting